A berbamine photoaffinity probe and its preparation method and application
By designing the berberine photoaffinity probe BBA-1, chemical proteomics technology was used to identify the target protein of BBM in liver cancer cells, revealing its molecular mechanism to inhibit the growth of liver cancer cells, and solving the target in the existing technology The unspecified issues provide new methods for the treatment of liver cancer.
Patent Information
- Application Number
- CN202310448723.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-24
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-04-24
AI Technical Summary
At present, the study has not yet clarified the target of berberine (BBM) in liver cancer cells, especially the molecular mechanism used in combination with sorafenib (SORA), and it is difficult to explain its specific mechanism in inhibiting the growth and apoptosis of liver cancer cells. .
A berberine photoaffinity probe BBA-1 was designed to explore the targets of BBM through chemical proteomics technology, and protein labeling is used to bind fluorescein or Biotin was tested to quantitatively identify target proteins in liver cancer cells.
Through the application of berberine photoaffinity probe, the molecular mechanism of BBM inhibition of liver cancer cell growth was revealed, and high confidence target proteins such as Plectin, Prosaposin, Annexin, and Calumenin were identified, providing a new method for liver cancer treatment. Helps optimize the structure and selectivity of BBM.
Smart Images

Figure CN116496285B_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of chemical proteomics, and in particular to a berbamine photoaffinity probe and a preparation method and application thereof. Background Art
[0002] Berbamine (BBM) is a natural compound extracted from the traditional Chinese medicine Funiu. Its unique chemical properties give it a potential sensitizing effect. It is used in clinical practice to treat a variety of diseases (such as autoimmune diseases, cancer and inflammation) [Diabetes, Metab; 2018, 11, 699-705]. Because it can promote the body's hematopoietic function and increase peripheral blood leukocytes, it is also used to prevent and treat leukopenia caused by chemotherapy or radiotherapy, benzene poisoning, radioactive substances and drug treatment in tumor patients. A large number of related studies have shown that the mechanism of action of BBM involves various key protocellular signaling pathways, especially showing good inhibitory activity against liver cancer cells both in vivo and in vitro [ACS Omega 2020, 5 (38), 24838-24847].
[0003] Sorafenib (SORA) is a targeted multikinase inhibitor and a standard first-line targeted therapy drug approved by the U.S. Food and Drug Administration for advanced hepatocellular carcinoma (HCC). In vitro tests have shown that it can inhibit tumor cell proliferation and anti-angiogenesis. Clinical practice evidence shows that the anti-tumor effect of SORA alone is poor and cannot completely inhibit the development of the disease. Therefore, it is necessary to develop new combination therapeutic drugs to improve the clinical efficacy of SORA. Current studies have found that BBM combined with the anti-liver cancer drug SORA can synergistically inhibit the growth of liver cancer cells and promote their apoptosis. It was further found that BBM can enhance the sensitivity of SORA to liver cancer cells by targeting the transcription factor STAT3-related signaling pathway [ACSOmega 2020, 5(38), 24838-24847].
[0004] Patent CN1810247A discloses the use of a berbamine derivative EBB in inhibiting the invasion and metastasis of human tumor cells. This type of substance inhibits the metastasis of tumor cells by protecting the basement membrane from damage. It has the significant effect of reducing the expression of MMP-2 and MMP-9, while enhancing the expression of TIMP, thereby increasing the TIMP / MMP ratio. However, the target of BBM in liver cancer cells is not mentioned.
[0005] Currently, studying the molecular mechanism of BBM's inhibition of liver cancer cell growth and finding the target of BBM at the cellular level, especially the molecular mechanism after combination with SORA, are technical issues that need to be solved urgently. Summary of the invention
[0006] In order to reveal the molecular mechanism of BBM, the present application provides a berbamine photoaffinity probe and a preparation method and application thereof, and uses chemical proteomics technology to explore the targets of BBM.
[0007] First, the present application designs a berbamine photoaffinity active molecular probe BBA-1. Since the derivatization modification of the BBM molecule at the hydroxyl group has the least effect on the activity of the original drug molecule, the photoaffinity probe provided by the present application uses BBM as the active group, and introduces a photocrosslinking group and a bioorthogonal group at its hydroxyl group, wherein the photocrosslinking group is diazirine, which can crosslink adjacent binding proteins in situ under ultraviolet light; the bioorthogonal group is an alkynyl group, which is coupled with fluorescein or biotin through a bioorthogonal coupling reaction, thereby detecting the probe labeling signal. The structure of this berbamine photoaffinity probe is shown in Formula I:
[0008]
[0009] Secondly, the present application also provides a method for preparing a berbamine photoaffinity probe, which is used to prepare the above-mentioned berbamine photoaffinity probe, comprising the following steps:
[0010] 1) Compound II is dissolved in an organic solvent, NaH is added under an ice bath, nitrogen is introduced for protection, Compound III is added, stirred, and reacted at room temperature to obtain a reaction solution containing a crude product of Compound I;
[0011] 2) adding water to the reaction solution containing the crude product of Compound I to quench, extracting the organic phase, removing water, concentrating and purifying by column chromatography to obtain a crude product of Compound I;
[0012] 3) Lyophilizing the crude product of compound I to obtain compound I, namely berbamine photoaffinity probe BBA-1.
[0013]
[0014] Furthermore, the molar ratio of compound II to compound III is 1:2.
[0015] Furthermore, the molar ratio of the compound II to NaH is 1:5.
[0016] Furthermore, the stirring time of adding compound III is 10 to 30 minutes; and the reaction time of reacting at room temperature is 36 to 60 hours.
[0017] Furthermore, the organic solvent is N,N-dimethylformamide, carbon tetrachloride or ethyl acetate.
[0018] Furthermore, the freeze-drying temperature is -80°C.
[0019] Furthermore, the extraction solvent for extracting the organic phase is ethyl acetate.
[0020] Finally, the present application also provides an application of a berbamine photoaffinity probe, which is used to discover the target protein of berbamine in liver cancer cells.
[0021] Furthermore, the target proteins are PLEC, SAP, ANXA2 and CALU.
[0022] This application uses chemical proteomics methods to reveal the molecular mechanism by which the natural product BBM inhibits the growth of liver cancer cells HCC-Lm3. For the first time, a photoaffinity probe corresponding to berbamine was designed and synthesized. The probe was used to quantitatively identify 986 potential BBA-binding proteins in liver cancer cells, and high-confidence target proteins such as Plectin, Prosaposin, Annexin, and Calumenin were identified by analyzing protein signal ratios and PSMs. The berbamine molecular probe provided in this application reveals the mechanism of action of BBM at the molecular level, identifies a series of important targets, and provides a new method for the treatment of liver cancer. The confirmation of protein targets will help to further optimize the structure of BBM, improve its specificity and selectivity, and become a preclinical candidate drug molecule, providing more opportunities for drug development. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The following is a brief description of the contents expressed in the drawings of the specification:
[0024] Figure 1 is the mass spectrum of BBA-1 prepared in Example 1 of the present application;
[0025] Figure 2 It is the BBA-1 prepared in Example 1 of this application. 1 H NMR spectrum;
[0026] Figure 3 It is the BBA-1 prepared in Example 1 of this application. 13 C NMR spectrum;
[0027] Figure 4 This is a diagram showing the labeling results of the BBA-1 probe in HCC-Lm3 cells in this application;
[0028] Figure 5 is a quantitative protein scatter plot of mass spectrometry results of BBA-1 binding protein analysis in this application;
[0029] Figure 6 is a relationship diagram between the quantitative protein ratio distribution and PSMs of the mass spectrometry results of the BBA-1 binding protein in this application;
[0030] Figure 7 It is a statistical graph of the number of differential proteins annotated for the target protein in this application;
[0031] Figure 8 This is the result diagram of GO enrichment analysis of differential proteins in this application. DETAILED DESCRIPTION
[0032] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0033] Example 1
[0034] Synthesis of Berbamine Photoaffinity Probe (BBA-1):
[0035]
[0036] BBM, i.e., compound II (300 mg, 0.49 mmol, 1.00 eq) and DMF (1.5 mL) were added to a 5 mL eggplant flask, and NaH (99 mg, 0.32 mmol, 5.00 eq) was added under ice bath, nitrogen was introduced for protection, and the mixture was stirred for 10 min under ice bath. A solution of compound III (244.5 mg, 0.99 mmol, 2.00 eq) in DMF (0.5 mL) was added to the reaction solution, and stirring was continued for 20 min under ice bath. The ice water was removed, and the eggplant flask containing the reaction solution was transferred to room temperature and reacted for 48 h to obtain a reaction solution containing a crude product of BBA-1.
[0037] 0.5 mL of water was added to the reaction solution, stirred for 5 min, the reaction solution was concentrated to dryness, and then 2 mL of water was added, and the mixture was repeatedly extracted with EtOAc (2 mL×4). The organic phase after extraction was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain 140.0 mg of a yellow oil, which was then freeze-dried to obtain 79.0 mg of a light yellow powder solid, which was the berbamine photoaffinity probe BBA-1 (yield: 21.20%).
[0038] The prepared BBA-1 was subjected to mass spectrometry and nuclear magnetic resonance analysis. Figure 1 , Figure 2 and Figure 3 The mass spectra of BBA-1, 1 H NMR spectra and 13 C NMR spectrum.
[0039] Target selectivity assessment of BBA-1
[0040] The target selectivity of the BBA-1 probe was evaluated based on the fluorescent gel analysis experiment. The liver cancer cell HCC-Lm3 was treated with BBA-1 and SORA at the same time. At this time, the probe BBA-1 bound to the target protein in the cell, and in situ illumination caused the BBA-1-bound protein to covalently cross-link with the probe, thereby stabilizing the interaction between the two. The use of photoaffinity strategy is particularly helpful in capturing the dynamic interaction between the probe and the protein. After the cell sample is lysed, fluorescein coupled, SDS-PAGE separated and gel fluorescence signal detected, the target selectivity of the probe BBA-1 in the cell can be read. The specific steps are as follows:
[0041] HCC-Lm3 cells were cultured in 6 cm culture dishes to a density of more than 85% (1.2 × 10 6 ,24 hours,number~2×10 6), remove the culture medium, and wash the cells twice with 5mL PBS. Add 2mL of serum-free culture medium containing different concentrations of BBA-1 probe to the cells (probe concentration is 0-100μM) and add 10μM SORA at the same time. Place the cells in a cell culture incubator and continue to incubate for 1 hour, then place the cell culture dish on ice, remove the culture dish cover, and irradiate with 365nm ultraviolet light under a UV crosslinker. The cell surface is 5-10cm away from the lamp tube and the light is irradiated for 15 minutes. After irradiation, gently scrape the cells with a cell scraper, collect them in a 1.5ml centrifuge tube, and wash them twice with cold PBS. Centrifuge at 3000rpm for 3 minutes at 4°C. The upper layer of PBS was removed, and the obtained cells were added with cell lysis buffer [PBS (ThermoFisher Scientific), 1% IGEPAL-CA-630 (Sigma-Aldrich), 0.2% SDS (Sigma-Aldrich), 1% EDTA-free protease inhibitor mixture (Sigma-Aldrich), 0.1% Benzonase (Beyotime)], and after ultrasonic disruption, the cells were centrifuged at high speed (20000g, 30 minutes) in a 4°C desktop centrifuge. The supernatant was taken, and the protein concentration was determined on an ELISA instrument using the BCA protein assay (Beyotime), and the concentration was adjusted to 2 mg / mL with cell lysis buffer. A final concentration of 200 μM fluorescein azide, 2.5 mM sodium ascorbate (Sigma-Aldrich), 25 mM BTTAA (CONFLUORE) and 12.5 mM CuSO4 (Innochem) were added at room temperature and reacted for 1 hour. After the above reaction, the samples were separated by SDS-PAGE and electrophoresed at 150V for about 1 hour. The gel was scanned with ChemiDoc imaging to display the fluorescent bands, and then stained with Coomassie blue. The results are as follows: Figure 4 shown.
[0042] from Figure 4 It can be seen that as the concentration of BBA-1 increases, the labeling signal of the band increases accordingly and significant labeling can be produced when the probe concentration is 25μM, and the signal gradually tends to saturation. The fluorescence signal reflects the type and intensity of the protein labeled by BBA-1. There are two significant labeling bands near 70kDa and 50kDa, respectively, and the labeling in other places is relatively weak, which shows the target selectivity of BBA-1.
[0043] BBA target identification based on high-resolution mass spectrometry
[0044] Based on the experimental results of the target selectivity evaluation of BBA-1, the chemical proteomics technology based on high-resolution mass spectrometry was used to quantitatively identify BBA-1 binding proteins. The core is to use the active molecular probe BBA-1 cross-linking labeling to directly bind proteins in living cells treated with 10μM SORA, and then couple the biotin reporter group through a bioorthogonal reaction, and use streptavidin magnetic beads to enrich the labeled proteins. After enzyme digestion, the enriched protein peptide samples are labeled with the help of dimethyl isotope labeling technology, and finally mass spectrometry analysis is performed to obtain the enriched target protein results. During the experiment, DMSO-treated cells were set as blank controls to reduce false positive results. The specific steps are as follows:
[0045] The probe-treated HCC-Lm3 cells stored at -80°C were placed on ice to thaw, and cell lysis buffer [PBS (ThermoFisher Scientific), 1% IGEPAL-CA-630 (Sigma-Aldrich), 0.2% SDS (Sigma-Aldrich), 1% EDTA-free protease inhibitor mixture (Sigma-Aldrich), 0.1% Benzonase (Beyotime)] was added, and after ultrasonic disruption, high-speed centrifugation (20000g, 30min) was performed in a 4°C desktop centrifuge. The supernatant was taken, and the protein concentration was determined on an ELISA instrument using the BCA protein assay (Beyotime), and the concentration was adjusted to 2 mg / mL using the cell lysis buffer. 200 μM fluorescein-biotin-azide (Biotin-PEG3-azide, TAB manufacturer), 2.5 mM sodium ascorbate (Sigma-Aldrich), 25 mM BTTAA (CONFLUORE) and 12.5 mM CuSO4 (Innochem) were added at room temperature and reacted for 1 hour. After the above reaction, the proteome was extracted with chloroform (Beijing Wokai Biotechnology Co., Ltd.)-methanol (Innochem) to remove excess reagents, and then the proteome was washed twice with cold methanol, resuspended in the enrichment buffer concentrate, ultrasonic-assisted dissolution, high-speed centrifugation (20000g, 2min) to remove possible precipitated impurities, and diluted with PBS to the final concentration of the enrichment buffer. At this time, 40 μL of the whole proteome solution was taken as the enrichment before sample. The protein solution was then rotated and incubated with streptavidin-coupled magnetic beads (200 μL, ThermoFisher) at room temperature for 3 hours. After the enrichment, the corresponding enzyme was added to digest the peptide overnight. After the enzyme digestion, dimethylation light labeling and heavy labeling were performed, and the samples were spun dry and loaded for mass spectrometry.
[0046] The mass spectrometry acquisition conditions are: positive ion mode, Orbitrap mass analyzer, primary spectrum scanning range 350 to 1800Da, resolution 60000, profile format, secondary spectrum data acquisition mode is data dependent, centroid format, the 20 ion peaks with the highest intensity are selected for secondary HCD (high-energy collision induced dissociation) fragmentation, and the secondary spectrum resolution is 15000. Other parameters that need to be set include isolation window, 1.6m / z units; default charge, 2+; normalized collision energy, 28%; maximum IT, 50ms; dynamic exclusion, 30.0s.
[0047] The MS data were searched and quantitatively analyzed using Thermo Proteomo Discoverer 2.5. The general parameters are shown in Table 1.
[0048] Table 1 General parameters for mass spectrometry acquisition
[0049] Enzyme TrypsinKR_C Database Uniport-human-filtered-reviewed Fix modification Carbamidomethyl[C] Variable modification Acetyl[ProteinN-term]; Oxidation[M]; Max missing cleavage number 2 MS tolerance 10ppm MSMS tolerance 20ppm FDR 1%
[0050] Using activity-based proteomic analysis, a series of chemical proteomics experiments were conducted in a liver cancer cell line (HCC-Lm3). The mass spectrometry data were filtered and analyzed using Thermo proteomo Discoverer2.5 software to exclude false positive results, and the Abundance Ratio (log2) was obtained by comparing the probe-treated labeled group and the DMSO control group. Combined with the actual target protein specific data, Abundance Ratio greater than 5 was finally selected as the screening condition. The results are shown in the figure. Figure 5 and Figure 6 As shown. Figure 5 It can be seen that a total of 1,397 direct target proteins of BBM were identified, of which 985 proteins had a ratio above 5 and were potential binding proteins. The PSMs (peptide-spectrum matches) of the candidate protein targets were analyzed. The higher the value, the higher the absolute intensity of the protein in the sample. Figure 6 It can be seen that the ratios and PSMs of Plectin (PlEC), Prosaposin (SAP), Annexin (ANXA2), and Calumenin (CALU) are very high, and the protein molecular weights are 53.2, 58.1, 38.4, and 37.1 kDa, respectively. Figure 4The rhodamine signal bands in the middle are consistent, which are high-confidence potential protein targets. Among them, SAP mainly stimulates the hydrolysis of glucosylceramide, PLEC plays an important role in maintaining the integrity of muscle fibers, ANXA2 is a calcium-regulated membrane-bound protein that can bind two calcium ions with high affinity, and CALU participates in the vitamin K-dependent carboxylation regulation of multiple N-terminal glutamic acid residues, all of which are important participants in cell physiological activities.
[0051] Analysis of key targets of BBA anti-cancer mechanism
[0052] 1) GO functional annotation classification
[0053] Taking into account the multi-target effects of natural products, and in order to fully understand the activity, functional positioning and biological processes involved in the target protein, the applicant uses Gene Ontology (GO) to target the candidate protein and then annotate the protein. GO, also known as GO term, is a classification system established to explain the biological functions of biological macromolecules. GO annotations are divided into the following three categories: biological process (BP), cellular component (CC) and molecular function (MF) (Kanehisa, M. et al. 2012). The number of differentially expressed proteins was statistically analyzed at the GO secondary functional annotation level. Figure 7 shown.
[0054] 2) GO enrichment analysis
[0055] In order to show the enrichment trend of differentially expressed proteins in GO annotated pathways, Fisher's exact test was performed on the differentially expressed proteins to obtain the enrichment of GO terms involved in the differentially expressed proteins. The functional classifications and pathways in which the differentially expressed proteins were significantly enriched were found by judging the significance level (pvalue) of the GO term enrichment. The top 10 significantly enriched GO terms (pvalue <= 0.05) were selected to draw an enrichment bubble diagram, such as Figure 8 shown.
[0056] from Figure 8It can be seen that the results of Biological Process enrichment showed significant enrichment in pathways such as cytoplasmic translation, rRNA processing, ribosome biogenesis, and rRNA metabolic process. The results of Cellular Component enrichment showed significant enrichment in pathways such as cytosolic ribosome, ribosomal subunit, ribosome, and mitochondrial protein-containing complex. The results of Molecular Function enrichment showed significant enrichment in pathways such as structural constituent of ribosome, rRNA binding, unfolded protein binding, and translation regulator activity. Therefore, the above analysis results all point to ribosome and cell cycle-related functional pathways, which is basically consistent with the literature [OncoTargets and Therapy 20191224; 12: 11437-11451]. This shows that after entering the cell, the BBM molecule is likely to specifically target the ribosome and inhibit the activity of ribosome-related proteins, thereby affecting the smooth progress of the cell cycle and causing cell death.
[0057] Obviously, the above embodiments are merely examples for the purpose of clear explanation, and are not intended to limit the implementation methods. For those skilled in the art, other different forms of changes or modifications can be made based on the above description. It is not necessary and impossible to list all the implementation methods here. The obvious changes or modifications derived therefrom are still within the scope of protection of the invention.
Claims
1. A berbamine photoaffinity probe, characterized in that: It has the structure shown in Formula I:
2. A method for preparing a berbamine photoaffinity probe, characterized in that: The method for preparing the berbamine photoaffinity probe according to claim 1 comprises the following steps: 1) Compound II is dissolved in an organic solvent, NaH is added under an ice bath, nitrogen is introduced for protection, Compound III is added, stirred, and reacted at room temperature to obtain a reaction solution containing a crude product of Compound I; 2) adding water to the reaction solution containing the crude product of Compound I to quench, extracting the organic phase, removing water, concentrating and purifying by column chromatography to obtain a crude product of Compound I; 3) Lyophilizing the crude product of Compound I to obtain Compound I; 3. The method for preparing a berbamine photoaffinity probe according to claim 2, characterized in that: The molar ratio of compound II to compound III is 1:
2.
4. The method for preparing a berbamine photoaffinity probe according to claim 2, characterized in that: The molar ratio of the compound II to NaH is 1:
5.
5. The method for preparing a berbamine photoaffinity probe according to claim 2, characterized in that: The stirring time of adding compound III is 10 to 30 minutes; the reaction time of placing the reaction under room temperature is 36 to 60 hours.
6. The method for preparing a berbamine photoaffinity probe according to claim 2, characterized in that: The organic solvent is N,N-dimethylformamide, carbon tetrachloride or ethyl acetate.
7. The method for preparing a berbamine photoaffinity probe according to claim 2, characterized in that: The freeze-drying temperature is -80°C.
8. The method for preparing a berbamine photoaffinity probe according to claim 2, characterized in that: The extraction solvent for extracting the organic phase is ethyl acetate.
9. An application of a berbamine photoaffinity probe, characterized in that: The berbamine photoaffinity probe of claim 1 is used to discover the target protein of berbamine in liver cancer cells, and the application does not involve the use of living human or animal bodies as direct implementation objects for diagnosing the cause of disease or treating diseases.
10. The use of a berbamine photoaffinity probe according to claim 9, characterized in that: The target proteins are PLEC, SAP, ANXA2 and CALU.
